Apollomics (APLM) Current Assets (2021 - 2025)

Apollomics (APLM) posted quarterly Current Assets of $6.1 million for Q4 2025, down 89.07% quarter-over-quarter from $55.4 million in Q2 2023.

Apollomics (APLM) Current Assets (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Current Assets for 4 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.

In Q4 2025, Current Assets changed N/A year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $6.1 million, changed N/A from the prior year.
Current Assets declined to $6.1 million in Q4 2025 per APLM's latest filing, from $55.4 million in the prior quarter.
Across five years, Current Assets topped out at $99.4 million in Q4 2021 and bottomed at $6.1 million in Q4 2025.
Historically, Current Assets has averaged $54.1 million across 4 years, with a median of $55.6 million in 2022.
On a YoY basis, Current Assets climbed as much as 43.86% in 2022 and fell as far as 43.86% in 2022.
Apollomics' Current Assets stood at $99.4 million in 2021, then tumbled by 43.86% to $55.8 million in 2022, then decreased by 0.74% to $55.4 million in 2023, then plunged by 89.07% to $6.1 million in 2025.
Business Quant data shows APLM's Current Assets at $6.1 million in Q4 2025, $55.4 million in Q2 2023, and $55.8 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	8.07 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.82 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	7.22 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.62 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.63 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	1.76 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	18.80 Bn
10	Apollomics	34.08 Mn	30.81 Mn	-	6.05 Mn

Download Data